4.7 Article

Coronary Atherosclerotic Precursors of Acute Coronary Syndromes

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 71, Issue 22, Pages 2511-2522

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2018.02.079

Keywords

acute coronary syndrome; atherosclerosis; clinical outcome; coronary artery disease; coronary computed tomography angiography

Funding

  1. National Institutes of Health [HL115150, R01 HL111141, R01 HL115150, R01 118019, U01 HL 105907]
  2. Leading Foreign Research Institute Recruitment Program of the National Research Foundation of Korea, Ministry of Science, ICT & Future Planning
  3. National Research Foundation of Korea - Ministry of Science and ICT [2012027176]
  4. Qatar National Priorities Research Program [09-370-3-089]
  5. GE Healthcare
  6. Biotronik
  7. Medtronic
  8. Boston Scientific
  9. Edwards Lifesciences
  10. CV Diagnostix
  11. HeartFlow
  12. Bracco
  13. Bayer
  14. Netherlands Heart Institute
  15. National Institutes of Health
  16. Phillips
  17. Volcano
  18. St. Jude Medical
  19. Abbott
  20. Gilead
  21. 480 Biomedical
  22. Abbott Vascular
  23. ART
  24. BioSensors International
  25. Celonova
  26. Claret Medical
  27. Cook Medical
  28. Cordis
  29. MicroVention
  30. OrbusNeich
  31. ReCord
  32. SINO Medical Technology
  33. Spectranetics
  34. Surmodics
  35. Terumo Corporation
  36. W.L. Gore
  37. Xeltis
  38. General Electric

Ask authors/readers for more resources

BACKGROUND The association of atherosclerotic features with first acute coronary syndromes (ACS) has not accounted for plaque burden. OBJECTIVES The purpose of this study was to identify atherosclerotic features associated with precursors of ACS. METHODS We performed a nested case-control study within a cohort of 25,251 patients undergoing coronary computed tomographic angiography (CTA) with follow-up over 3.4 +/- 2.1 years. Patients with ACS and nonevent patients with no prior coronary artery disease (CAD) were propensity matched 1:1 for risk factors and coronary CTA-evaluated obstructive (>= 50%) CAD. Separate core laboratories performed blinded adjudication of ACS and culprit lesions and quantification of baseline coronary CTA for percent diameter stenosis (%DS), percent cross-sectional plaque burden (PB), plaque volumes (PVs) by composition (calcified, fibrous, fibrofatty, and necrotic core), and presence of high-risk plaques (HRPs). RESULTS We identified 234 ACS and control pairs (age 62 years, 63% male). More than 65% of patients with ACS had nonobstructive CAD at baseline, and 52% had HRP. The %DS, cross-sectional PB, fibrofatty and necrotic core volume, and HRP increased the adjusted hazard ratio (HR) of ACS (1.010 per %DS, 95% confidence interval [CI]: 1.005 to 1.015; 1.008 per percent cross-sectional PB, 95% CI: 1.003 to 1.013; 1.002 per mm(3) fibrofatty plaque, 95% CI: 1.000 to 1.003; 1.593 per mm3 necrotic core, 95% CI: 1.219 to 2.082; all p < 0.05). Of the 129 culprit lesion precursors identified by coronary CTA, three-fourths exhibited <50% stenosis and 31.0% exhibited HRP. CONCLUSIONS Although ACS increases with %DS, most precursors of ACS cases and culprit lesions are nonobstructive. Plaque evaluation, including HRP, PB, and plaque composition, identifies high-risk patients above and beyond stenosis severity and aggregate plaque burden. Published by Elsevier on behalf of the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available